Unicycive Therapeutics stock faces March FDA decision after NDA acceptance
Published on 10/31/2026 at 00:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA Review Sets Next Catalyst
- The FDA accepted Unicycive's resubmitted application for oxylanthanum carbonate.
- The agency set a PDUFA target action date of March 25, 2027.
- The application includes manufacturing data from a new drug product vendor.
Unicycive Therapeutics is heading toward a defined regulatory milestone after the U.S. Food and Drug Administration accepted the company's resubmitted New Drug Application for oxylanthanum carbonate on October 21, 2026. The agency set a March 25, 2027, Prescription Drug User Fee Act target action date for the application, according to the Unicycive investor release.
The application covers oxylanthanum carbonate, an investigational oral phosphate binder for hyperphosphatemia in patients with chronic kidney disease who are on dialysis. The FDA classified the resubmission as a Class II review with a six-month review period. The filing follows a Complete Response Letter received in June 2026 and includes Chemistry, Manufacturing, and Controls data from a new drug product manufacturing vendor.
Regulatory Path Narrows
The new filing gives investors a specific date to monitor, but FDA acceptance does not guarantee approval. The company is pursuing the 505(b)(2) pathway. A separate analysis by Tickeron identifies regulatory execution, reimbursement and financing as key sensitivities for the clinical-stage biotechnology company.
Unicycive's after-hours quote was 3.74 US dollars on Nasdaq at 10:00 p.m. CET on Friday, October 30, 2026. The quote was in US dollars and no Xetra comparison is included.
Company Focus And Competition
Unicycive Therapeutics is a U.S.-based biotechnology company headquartered in Los Altos, California. It develops treatments for kidney diseases, with oxylanthanum carbonate aimed at hyperphosphatemia in dialysis patients and UNI-494 focused on acute kidney injury. The company is a small, clinical-stage specialist compared with broader biotechnology peers such as Moderna, Regeneron Pharmaceuticals and Incyte, which Tickeron lists among notable companies in the wider biotechnology group.
Unicycive Therapeutics at a Glance
- Company: Unicycive Therapeutics, Inc.
- Ticker: UNCY
- Exchange: Nasdaq
- Quote: 3.74 US dollars, after-hours, October 30, 2026, 10:00 p.m. CET
- Change: -0.07 US dollars, or -1.84 percent, versus the previous close
- 52-week range: 3.35 to 8.74 US dollars
- Sector: Healthcare
- Industry: Biotechnology
Broader market conditions remain relevant for small biotechnology companies because financing costs and risk appetite can influence capital access. Current market reports provide the wider S&P 500 context.
